Alaunos Therapeutics, Inc. (TCRT)
Health Care ยท Pharmaceutical Preparations
Alaunos Therapeutics, Inc. (TCRT) is listed on Nasdaq, where its shares have traded since August 24, 2005. SentiSense covers Alaunos Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. The company reports 1 employees, and its corporate website is www.alaunos.com.
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
Latest reported results
Alaunos Therapeutics, Inc. reported revenue of $0.00 for Q2 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 27 institutions reported holding TCRT, with 90,383 shares worth $204,421 in aggregate. The largest reported holders were Vanguard, BlackRock and Geode Capital Management. Of the 5 largest reported holders, 1 added shares, 2 reduced their positions and 2 held their positions unchanged during the quarter.
More on TCRT
- TCRT sentiment: whether news and social coverage of Alaunos Therapeutics, Inc. leans bullish or bearish, and the stories driving it.
- TCRT ownership: all 27 reporting institutions, plus insider and congressional trades.
- TCRT financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
SentiSense also tracks daily options readings for Alaunos Therapeutics, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Alaunos Therapeutics, Inc. do?
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease).
What sector is TCRT in?
SentiSense classifies Alaunos Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does TCRT stock trade?
Alaunos Therapeutics, Inc. (TCRT) is listed on Nasdaq, where its shares have traded since August 24, 2005.
How many institutions own TCRT?
27 institutions reported a position in TCRT in 13F filings for the quarter ended June 30, 2026, worth $204,421 in total.